Home Business & Finance Stock market: Evotec share price down – 01/14/22 – News

Stock market: Evotec share price down – 01/14/22 – News

7
0
Stock market: Evotec share price down - 01/14/22 - News

Friday, 14.01.2022 11:01 from ARIVA.DE | Views: 20 The stock prices at a glance. © gopixa / iStock / Getty Images Plus / Getty Images http://www.gettyimages.de/ Trade Evotec shares permanently for 0 euros! Now on Smartbroker.de The security of Evotec (Evotec share) listed a little lighter on Friday. Most recently, investors paid EUR 35.89 for the paper. Evotec’s shares are currently down 2.53 percent. It has deteriorated by 93 cents compared to the last price of the previous day. On the stock market, investors are currently paying EUR 35.89 for the share. If you use the TecDAX (TecDAX ) as a benchmark, then Evotec shares lag behind. With a score of 3,564 points, the TecDAX is currently down 0.80 percent on the last trading day. Evotec’s share price recorded its lowest price to date on June 4, 2012. At that time, the share price was EUR 1.87, which is EUR 34.02 less than it currently is.

The company Evotec

Evotec SE is one of the world’s leading drug discovery and development companies. The company specializes in neural diseases, pain, metabolic and inflammatory diseases and oncology. The core business is drug research, which is carried out in cooperation with partner companies from the pharmaceutical and biotechnology industries. Evotec sold goods and services worth EUR 501 million in the past financial year. The company made a bottom line profit of EUR 6.30 million. New business figures are expected for April 12, 2022.

That’s how it is with the competition

Evotec aap implants 2Invest Medigene MorphoSys PerkinElmer
course 35.89 €13.00 €2.87 €30.10 €158.35
performance 2.53 0.00% -0.76% -0.86% -4.17% +0.99%
market cap €5.90 billion €74.7 million €70.5 million €1.03 billion €17.7 billion

This article was created by ARIVA.DE standardized using company information from Finance Base. Read more advertising

further down?

Position in Evotec in the short term
Ask: 6.32 Leverage: 6.89
with moderate leverage

Morgan Stanley The Base Prospectus, Final Terms and Key Information Documents are available from: MD13UJ,. Please also note the further information on this advertisement. The issuer is entitled to call open-end securities. Advertisement Subscribe to more news about the Exasol share free of charge Note: ARIVA.DE publishes analyses, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that has been posted by third parties in the “News” area of ​​this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and/or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.

Other users were also interested in this article:



#Stock #market #Evotec #share #price #News

LEAVE A REPLY

Please enter your comment!
Please enter your name here